Consanguity

Take a walk through microcap life sciences companies. 

Eighty percent failure rate in pursuit of molecules. Funded by equity. Consanguity between boards, management, and a cul de sac of institutional money. Price  determined by a dedicated group of gatekeepers writ large.

Expectations are inflated by scribes compensated for their efforts with prose rubbing against inconvenient fictions to be met with the discard of species as frisbees in a system that avoids boomerangs. 

The bride and groom are wedded to a promised Covid 19 vaccine that surfaces every quarter. The Honig cast reprised its act that turned an Akers into an MyMd and a Cystron into an Oravax Medical. 

Magic that raised $200 million from capital markets to the incredulity of none.